---
title: "002393.SZ (002393.SZ) — 相關新聞"
type: "Symbol"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/quote/002393.SZ/news.md"
symbol: "002393.SZ"
name: "002393.SZ"
parent: "https://longbridge.com/zh-HK/quote/002393.SZ.md"
datetime: "2026-03-10T22:42:36.171Z"
locales:
  - [en](https://longbridge.com/en/quote/002393.SZ/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/002393.SZ/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/002393.SZ/news.md)
---

> 支持的語言: [English](https://longbridge.com/en/quote/002393.SZ/news.md) | [简体中文](https://longbridge.com/zh-CN/quote/002393.SZ/news.md)


# 002393.SZ (002393.SZ) — 相關新聞

### [Tianjin Development's subsidiary Lishengpharma earned 1.27 times more last year, reaching 418 million yuan](https://longbridge.com/zh-HK/news/278467376.md)
*2026-03-09T23:54:00.000Z*
> Tianjin Development announced that its subsidiary Lishengpharma (Shenzhen: 002393) reported a net profit attributable to

### [Tianjin Development’s Lisheng Pharma Unit Posts Strong 2025 Preliminary Profit Surge](https://longbridge.com/zh-HK/news/278456267.md)
*2026-03-09T22:37:32.000Z*
> Tianjin Development Holdings announced that its subsidiary, Tianjin Lisheng Pharmaceutical, reported strong preliminary 

### [Lishengpharma's net profit attributable to the parent company for the year 2025 is 418 million yuan, an increase of 126.72%](https://longbridge.com/zh-HK/news/278371583.md)
*2026-03-09T10:21:03.000Z*
> Lishengpharma released its performance preliminary report for 2025, with total operating revenue of 1.393 billion yuan, 

### [Lishengpharma received the drug registration certificate for Voriconazole tablets](https://longbridge.com/zh-HK/news/277898208.md)
*2026-03-05T07:51:04.000Z*
> Lishengpharma announced that the company has obtained the drug registration certificates for Voriconazole Tablets in 0.2

### [Lishengpharma: The drug Voriconazole tablets have passed the market authorization application](https://longbridge.com/zh-HK/news/277898124.md)
*2026-03-05T07:48:41.000Z*
> Lishengpharma announced that the company recently received the "Drug Registration Certificate" issued by the National Me

### [China Biopharmaceutical: The Phase III clinical trial of Vitreotide's "CLDN18.2 ADC" has completed subject enrollment](https://longbridge.com/zh-HK/news/275237589.md)
*2026-02-08T22:21:03.000Z*
> SINO BIOPHARM announced that its wholly-owned subsidiary, Lixin Pharmaceutical Technology, has completed patient enrollm

### [Lishengpharma: Adenosine phosphate raw materials have passed the listing application](https://longbridge.com/zh-HK/news/275091721.md)
*2026-02-06T07:56:37.000Z*
> Lishengpharma announced that the company has received the "Approval Notice for the Market Application of Chemical Raw Ma

### [Lishengpharma: The specification of Aminophylline Tablets 0.1g has passed the consistency evaluation of generic drugs](https://longbridge.com/zh-HK/news/274110546.md)
*2026-01-29T07:45:46.000Z*
> Lishengpharma announced that the company has received the "Drug Supplement Application Approval Notice" issued by the Na

### [](https://longbridge.com/zh-HK/news/273751589.md)
*2026-01-26T21:58:38.000Z*
> Trump: I hereby raise the tariffs on South Korean automobiles, timber, pharmaceuticals, and all other equivalent tariff